9-valent HPV Vaccine in Postpartum Women

Inclusion Criteria: * Female between the ages of 16 and 45 years of age at enrollment * Postpartum (Day 1 vaccination to occur within 1 week of delivery) * Judged to be in good health on the basis of medical history and physical examination * Able to fully understand study procedures, alternative treatments available, the risks involved in the study and voluntarily agrees to participate by giving written informed consent * Able to read, understand, and complete the questionnaires Exclusion Criteria: * Has a known allergy to any vaccine component, including aluminum, yeast, or BENZONASE™ * Has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections * Is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition. * Is receiving or has received in the year prior to enrollment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide, TNF-α antagonists, monoclonal antibody therapies (including rituximab), intravenous gamma globulin (IVIG), antilymphocyte sera, or other therapy known to interfere with the immune response. With regard to systemic corticosteroids, a subject will be excluded if she is currently receiving steroid therapy, has recently (within 2 weeks of enrollment) received such therapy, or has received 2 or more courses of high dose corticosteroids (orally or parenterally) lasting at least 1 week in duration in the year prior to enrollment. The use of inhaled, nasal, or topical steroids are considered eligible for the study * Has received any immune globulin product (including RhoGAM™) or other blood- derived product within 3 months prior to Day 1 vaccination or plans to receive such product during the study * Has received a marketed HPV vaccine * Has had a fever of \> 100° within 24-hour period prior to the Day 1 vaccination